• CHK1 Inhibition in Receptor-Stratified Breast Cancer

  2026-10-09

  Xu and colleagues showed that CHK1 inhibition has different therapeutic implications across breast cancer models defined by ER, PR, and HER2 status. The study’s central innovation was to connect receptor context with distinct mechanisms of chemotherapy sensitization and single-agent activity, supporting biomarker-informed interpretation of CHK1-targeted strategies.

• WRN–MSI Synthetic Lethality in Colorectal Cancer

  2026-10-08

  The reference study identifies a p53/PUMA-mediated apoptotic mechanism underlying the selective vulnerability of mismatch repair-deficient, microsatellite-instability colorectal cancers to Werner helicase loss. Its genetic, pharmacological, and xenograft evidence supports WRN as a context-dependent therapeutic target, particularly in p53-wildtype MSI tumors, while also highlighting the need to distinguish WRN biology from broader RecQ helicase inhibition.

• Mestranol and Reversible Lysosomal Stress in Microglia

  2026-10-08

  A 2026 Aquatic Toxicology study identifies mestranol as an inducer of a reversible lysosomal storage–like state in zebrafish microglia. The findings separate preserved phagocytic uptake from impaired intracellular digestion and provide a live model for studying environmental estrogen-associated neuroimmunotoxicity.

• Gingerenone A, LDHA, and Sunitinib Resistance

  2026-10-07

  A January 2026 study reports that gingerenone A suppresses LDHA-associated glycolysis and improves sunitinib response in renal cell carcinoma models. Its central contribution is a preclinical mechanistic link between metabolic intervention, HIF-1α–angiogenic signaling, and reversal of treatment resistance, although clinical relevance remains to be established.

• RWJ 67657 and the Next p38 Strategy

  2026-10-07

  RWJ 67657, also known as JNJ-3026582, offers a useful lens for connecting selective p38α/β inhibition with activation-loop dephosphorylation. This thought-leadership analysis separates established findings from translational hypotheses and outlines how researchers can evaluate its relevance to inflammatory disease research.

• Novel Allosteric PDK4 Inhibitors: Study Insights

  2026-10-06

  Lee and colleagues identified a new anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, with compound 8c showing 84 nM in vitro activity and evidence of metabolic, allergic, and cancer-related effects. The study supports PDK4 as a tractable metabolic target while leaving important questions about selectivity, mechanism, pharmacology, and clinical translation.

• Doxorubicin Beyond the Product Page

  2026-10-06

  Doxorubicin, also known as Adriamycin, remains a powerful translational reference compound because it links DNA damage, chromatin disruption, apoptosis, and therapeutic trade-offs. This thought-leadership analysis places its mechanism alongside historical small-cell lung cancer evidence, outlines validation priorities, and defines how researchers can extract stronger biological insight without overextending preclinical findings.

• IL-7 and ER Proteostasis in SARS-CoV-2 Research

  2026-10-05

  A translational perspective on how SARS-CoV-2 PLpro reshapes ER protein control—and why IL-7 research should be interpreted within a broader immune-state framework.

• Sulfo-Cy3 azide and Claustrum Development

  2026-10-05

  Explore how the Sulfo-Cy3 azide bioconjugation reagent can be interpreted within a rigorous framework for developmental neuroscience. This evidence-led article separates fluorescent signal quality from claims about Nurr1-positive neuron birth timing, identity, and spatial organization.

• Demethyleneberberine Induces NSCLC Senescence

  2026-10-04

  A 2021 Phytomedicine study reports that Demethyleneberberine suppresses NSCLC cell growth by linking c-Myc/HIF-1α downregulation to cell-cycle arrest and cellular senescence. The work provides preclinical mechanistic evidence for DMB in non-small cell lung cancer research, while remaining limited to cell models and xenograft-level validation.

• Trilaurin: From Lipid Excipient to Biocatalytic Evidence

  2026-10-03

  Trilaurin, also known as Glycerol Tridodecanoate, is more than a water-insoluble lipid: it is a defined substrate and formulation component whose evidence varies by application. This article separates established chemistry from emerging drug-delivery hypotheses and examines the significance of a reported enzymatic route to laurylamine.

• Doxorubicin, SMYD2, and the Logic of Resistance

  2026-10-02

  Doxorubicin is more than a cytotoxic benchmark: it is a mechanistic probe for studying topoisomerase II injury, apoptosis, chromatin disruption, and multidrug resistance. This article connects Doxorubicin research with SMYD2–miR-125b–P-glycoprotein biology in clear cell renal cell carcinoma and offers a translational framework for designing more informative combination studies.

• 1,2-Dioleoyl-sn-glycero-3-PE (DOPE) Workflow

  2026-10-01

  1,2-Dioleoyl-sn-glycero-3-PE (DOPE), SKU C4956, is a helper phospholipid for cationic liposomes and lipid nanoparticle formulations intended to improve intracellular nucleic acid release. It should be evaluated as part of a defined lipid mixture, not used as a standalone aqueous reagent or interpreted as a validated therapeutic component without application-specific testing.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide

  2026-10-01

  Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, frozen and paraffin IHC, flow cytometry, and ELISA workflows. It should not be used as a primary antibody, for direct antigen detection, or as a substitute for a secondary antibody matched to non-goat immunoglobulins.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody

  2026-09-30

  Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, frozen or paraffin IHC, flow cytometry, and ELISA workflows. It should not be used as a universal secondary antibody for non-goat primaries, and assay-specific dilution, blocking, and incubation conditions require validation.

8171 records 1/545 page Next 12345 下5页 Last page